We are live on ! Find out more
BBC icon

Virtus Biotech Clinical Trials ETF
BBC

13 hedge funds and large institutions have $5.39M invested in Virtus Biotech Clinical Trials ETF in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

43% more capital invested

Capital invested by funds: $3.78M → $5.39M (+$1.62M)

7% less funds holding

Funds holding: 14 → 13 (-1)

Holders
13
Holders Change
-1
Holders Change %
-7.14%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SG Americas Securities
SG Americas Securities
New York
+$450K
2
CCP
Cardan Capital Partners
Colorado
+$239K
3
Jane Street
Jane Street
New York
+$233K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$150K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$71.6K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$291K
2
LPL Financial
LPL Financial
California
-$97.7K
3
LTFS
Ladenburg Thalmann Financial Services
Florida
-$13.3K
4
MFS
MSI Financial Services
Massachusetts
-$5.82K
5
TRCT
Tower Research Capital (TRC)
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$2.27M – – –
SG Americas Securities
2
SG Americas Securities
New York
$688K +$450K +21,970 +262%
Jane Street
3
Jane Street
New York
$610K +$233K +11,380 +73%
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$569K +$150K +7,300 +41%
LPL Financial
5
LPL Financial
California
$425K -$97.7K -4,770 -20%
Royal Bank of Canada
6
Royal Bank of Canada
Ontario, Canada
$318K +$71.6K +3,493 +33%
CCP
7
Cardan Capital Partners
Colorado
$264K +$239K +11,674 New
Morgan Stanley
8
Morgan Stanley
New York
$90K +$53.3K +2,600 +190%
LTFS
9
Ladenburg Thalmann Financial Services
Florida
$83K -$13.3K -651 -15%
MFS
10
MSI Financial Services
Massachusetts
$25K -$5.82K -284 -20%
WRM
11
Westport Resources Management
Connecticut
$23K +$20.5K +1,000 New
Creative Planning
12
Creative Planning
Kansas
$20K – – –
NFG
13
Next Financial Group
Texas
$15K +$14K +681 New
Citadel Advisors
14
Citadel Advisors
Florida
– -$291K -16,139 Closed
TRCT
15
Tower Research Capital (TRC)
New York
– -$1K -81 Closed

BBC Hedge Fund Activity: Q3 2016 in Review

13 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q3 2016, worth a combined $5.39M — up 43% from $3.78M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BBC positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.

The largest buyer was SG Americas Securities, adding an estimated $450K. The largest seller was Citadel Advisors, exiting entirely with an estimated $291K sold.

  • 13 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q3 2016, down from 14 in Q2 2016.
  • Funds reported $5.39M of Virtus Biotech Clinical Trials ETF stock for Q3 2016, up 43% quarter-over-quarter.
  • 3 funds opened new Virtus Biotech Clinical Trials ETF positions in Q3 2016 and 2 closed out, a net change of +1 holder.
  • The largest Virtus Biotech Clinical Trials ETF buyer in Q3 2016 was SG Americas Securities, an estimated $450K added.
  • The largest Virtus Biotech Clinical Trials ETF seller in Q3 2016 was Citadel Advisors, an estimated $291K sold.

Based on aggregated 13F filings for Q3 2016.